Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal ...

ZORYVE foam 0.3% was safe, well-tolerated, and demonstrated durable and continuously improving efficacy in the treatment of seborrheic dermatitis ...
OK Magazine on MSN

'Hopeful' Tori Spelling Is Embracing Her 'Second Chapter' of Life: 'I'm Much Better'

Tori Spelling is embracing this new "chapter" she's in following a tough few years. "Everything's a journey, and it's always ...

Veterinary Monoclonal Antibodies Market Research Global Forecast Report 2025: A $3.06 Billion Market by 2030, Driven by Upcoming Technologies, R&D Activities, an…

The global veterinary monoclonal antibodies market is set to surge, reaching USD 3.06 billion by 2030, up from USD 1.70 ...

Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today ...